Contineum Therapeutics Inc (CTNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 31.21 is considered Undervalued compared with the five-year average of -6.65. The fair price of Contineum Therapeutics Inc (CTNM) is between 15.32 to 37.73 according to relative valuation method. Compared to the current price of 14.65 USD , Contineum Therapeutics Inc By Undervalued By 4.4%.

Relative Value

Fair Zone

15.32-37.73

Current Price：14.65

4.4%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Contineum Therapeutics Inc (CTNM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Contineum Therapeutics Inc (CTNM) has a current Price-to-Book (P/B) ratio of 1.84. Compared to its 3-year average P/B ratio of 1.24, the current P/B ratio is approximately 48.61% higher. Relative to its 5-year average P/B ratio of 1.24, the current P/B ratio is about 48.61% higher. Contineum Therapeutics Inc (CTNM) has a Forward Free Cash Flow (FCF) yield of approximately -15.89%. Compared to its 3-year average FCF yield of -14.45%, the current FCF yield is approximately 10.00% lower. Relative to its 5-year average FCF yield of -14.45%, the current FCF yield is about 10.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CTNM competitors is 69.03, providing a benchmark for relative valuation. Contineum Therapeutics Inc Corp (CTNM.O) exhibits a P/S ratio of 31.21, which is -54.79% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CTNM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CTNM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CTNM currently overvalued or undervalued?

Contineum Therapeutics Inc (CTNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 31.21 is considered Undervalued compared with the five-year average of -6.65. The fair price of Contineum Therapeutics Inc (CTNM) is between 15.32 to 37.73 according to relative valuation method. Compared to the current price of 14.65 USD, Contineum Therapeutics Inc is Undervalued By 4.40%.

What is Contineum Therapeutics Inc (CTNM) fair value?

CTNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Contineum Therapeutics Inc (CTNM) is between 15.32 to 37.73 according to relative valuation method.

How does CTNM's valuation metrics compare to the industry average?

The average P/S ratio for CTNM's competitors is 69.03, providing a benchmark for relative valuation. Contineum Therapeutics Inc Corp (CTNM) exhibits a P/S ratio of 31.21, which is -54.79% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Contineum Therapeutics Inc (CTNM) as of Mar 02 2026?

As of Mar 02 2026, Contineum Therapeutics Inc (CTNM) has a P/B ratio of 1.84. This indicates that the market values CTNM at 1.84 times its book value.

What is the current FCF Yield for Contineum Therapeutics Inc (CTNM) as of Mar 02 2026?

As of Mar 02 2026, Contineum Therapeutics Inc (CTNM) has a FCF Yield of -15.89%. This means that for every dollar of Contineum Therapeutics Inc's market capitalization, the company generates -15.89 cents in free cash flow.

What is the current Forward P/E ratio for Contineum Therapeutics Inc (CTNM) as of Mar 02 2026?

As of Mar 02 2026, Contineum Therapeutics Inc (CTNM) has a Forward P/E ratio of -5.76. This means the market is willing to pay $-5.76 for every dollar of Contineum Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Contineum Therapeutics Inc (CTNM) as of Mar 02 2026?

As of Mar 02 2026, Contineum Therapeutics Inc (CTNM) has a Forward P/S ratio of 31.21. This means the market is valuing CTNM at $31.21 for every dollar of expected revenue over the next 12 months.

CTNM Valuation